Transtat 500 Dosage & Drug Information

Concise Prescribing Info Full Prescribing Info Contents Description Action Indications/Uses Dosage/Direction for Use Overdosage Contraindications Special Precautions Use In Pregnancy & Lactation Adverse Reactions Drug Interactions Storage MIMS Class ATC Classification Regulatory Classification Presentation/Packing

Concise Prescribing Info

Contents

Tranexamic acid

Indications/Uses

Short-term use for hemorrhage or risk of hemorrhage in increased fibrinolysis or fibrinogenolysis. Local fibrinolysis in prostatectomy & bladder surgery; menorrhagia; epistaxis; conisation of the cervix; traumatic hyphema; hereditary angioneurotic edema; management of dental extraction in hemophiliacs.

Click to view Transtat 500 detailed prescribing information

Dosage/Direction for Use

Local fibrinolysis 15-25 mg/kg (2-3 tab) bid-tid. Prostatectomy 2 tab tid-qid until macroscopic hematuria is no longer present. Menorrhagia 2 tab tid up to 4 days, may be increased w/ very heavy menstrual bleeding. Max: 4 g daily (8 tab). Epistaxis 2 tab tid for 7 days. Conisation of the cervix 3 tab tid. Traumatic hyphema 2-3 tab tid. Dose is based on 25 mg/kg tid. Hereditary angioneurotic edema Intermittently 2-3 tab bid-tid for some days. Hemophilia in the management of dental extractions 2-3 tab every 8 hr. Dose is based on 25 mg/kg. Mild to moderate renal insufficiency serum creatinine 250-500 μmol/L 15 mg/kg daily, 120-249 μmol/L 15 mg/kg bid. Childn 25 mg/kg/dose.

Click to view Transtat 500 detailed prescribing information

Overdosage

View Transtat 500 overdosage for action to be taken in the event of an overdose.

Administration

May be taken with or without food: Swallow whole, do not chew/break.

Contraindications

Hypersensitivity. Active thromboembolic disease. History of venous or arterial thrombosis; convulsions. Fibrinolytic conditions following consumption coagulopathy. Severe renal impairment.

Click to view Transtat 500 detailed prescribing information

Special Precautions

Risk of mechanical anuria due to formation of ureteral clot. Perform regular eye exam & LFTs in long-term treatment of patients w/ hereditary angioneurotic edema. Not to be used in patients w/ irregular menstrual bleeding. Increased risk of thrombosis in patients receiving OCs. Previous thromboembolic event & family history of thromboembolic disease (eg, thrombophilia). Not recommended in cases of increased fibrinolysis due to disseminated intravascular coagulation. Discontinue treatment in patients who experience visual disturbances. Convulsions. Increased blood levels in patients w/ renal insufficiency. Pregnancy & lactation. Menorrhagic childn <15 yr.

Click to view Transtat 500 detailed prescribing information

Use In Pregnancy & Lactation

Click to view Transtat 500 detailed prescribing information

Drug Interactions

May counteract the thrombolytic effect of fibrinolytic prep.

Click to view Transtat 500 detailed prescribing information

Storage

View Transtat 500 storage conditions for details to ensure optimal shelf-life.

Description

View Transtat 500 description for details of the chemical structure and excipients (inactive components).

Action

View Transtat 500 mechanism of action for pharmacodynamics and pharmacokinetics details.

MIMS Class

Haemostatics

ATC Classification

B02AA02 - tranexamic acid ; Belongs to the class of amino acid antifibrinolytics. Used in the treatment of hemorrhage.

Regulatory Classification

Presentation/Packing

Form

Transtat 500 FC tab 500 mg

Packing/Price

60's (P26.95/film-coated tab, P1,617/box)

Transtat 500

tranexamic acid

Manufacturer:

Kusum Healthcare

Distributor:

Kusum Healthcare